WSJ ran a piece on people who used GLP-1s for weight loss and later ended up in treatment for anorexia:

 https://www.wsj.com/health/wellness/glp1-anorexia-wegovy-mounjaro-1bf4035c

Worth reading alongside the primary literature from the past few months, because the reporting is no longer just anecdotal.

A JAMA Psychiatry survey published this summer (Levinson and colleagues) recruited 436 people with diagnosed eating disorders in 2025 and asked about GLP-1 use. Just over 32% reported having ever used one, and 22% reported current use. Broken out by diagnosis, a little over 50% of participants with binge eating disorder reported use, about 42% of those with atypical anorexia nervosa, roughly 30% of those with ARFID, over 25% of those with bulimia, and about 11% of those with anorexia nervosa. Roughly 10% obtained them through online providers prescribing compounded formulations. Over 10% reported misuse, defined as taking more or less than prescribed, using longer than prescribed, tampering with injection equipment, or sharing without a prescription.

The authors described the weight loss market as a rapidly evolving risk environment for this population.

Summary of the findings:

 https://www.medscape.com/viewarticle/many-eating-disorder-patients-using-glp-1s-2026a1000lym

In April, NEJM published a perspective by Amanda Banks raising the same concern from the prescribing side. She noted the share of GLP-1 prescriptions written for people who were not diabetic, obese, or overweight rose from 4.5% in 2018 to 17% in 2023, and argued for consensus recommendations to protect people with existing or emerging eating disorders. A 2023 FDA analysis found misuse reports for semaglutide were roughly four times higher than for other GLP-1 drugs.

NEJM perspective:

 https://www.nejm.org/doi/full/10.1056/NEJMp2600300

Clinician-side reporting describes the same pattern from treatment centers, including patients presenting at very low BMI while still dosing.

NPR, February 2026: https://www.npr.org/2026/02/04/nx-s1-5677633/glp-1-obesity-wegovy-zepbound-eating-disorders-anorexia-bulimia

Washington Post, May 2026: https://www.washingtonpost.com/health/2026/05/23/weight-loss-drugs-pose-dangers-people-with-eating-disorders/

MindSite News, May 2026: https://mindsitenews.org/2026/05/29/glp-1-access-a-problem-for-people-with-eating-disorders/

The mechanism cuts both ways, which is part of why this is hard to legislate around. A 2025 systematic review and meta-analysis found GLP-1 agonists reduced Binge Eating Scale scores by about 8 points, though the pooled sample was only 182 participants across five studies and heterogeneity was high. WSJ also covered that side on July 13 in a piece on clinicians treating certain eating disorders with these drugs. The same appetite and reward suppression that helps in binge-type presentations appears to reinforce restriction in people with a restrictive history. Same drug class, opposite clinical valence depending on phenotype.

Meta-analysis: https://link.springer.com/article/10.1007/s40519-025-01720-9

Penn Medicine's eating disorder program has said outright that no protocol exists to screen for eating disorders before prescribing GLP-1 receptor agonists. That gap widens with telehealth and disappears entirely outside a clinical relationship.

Penn Medicine:

 https://www.pennmedicine.org/physicians-hub/physician-article/implications-of-glp-1-medications-for-eating-disorder-care

ANAD clinical guidance:

 https://anad.org/learning-library/glp-1-medications-eating-disorders/

Anyone that is on tirz take a low dose of reta? I currently am on tirz but have heard of others doing this. I am just curious to see if many others do this?

By Lisa DiFrancesco, MD | DiFrancesco Plastic Surgery | Atlanta, GA

Every peptide I have covered in this series — CJC-1295, AOD-9604, TB-500, BPC-157, Thymosin Alpha-1 — has been something I approach primarily as a physician in the integrated medicine space: compounds with compelling mechanistic rationale, variable human evidence, and important clinical nuance that my patients deserve to hear accurately.

GHK-Cu is different. GHK-Cu is personal.

As a plastic surgeon who works daily at the intersection of tissue injury and healing — who thinks about collagen quality, wound architecture, scar formation, skin remodeling, and hair restoration every single day — this is the peptide that sits closest to what I actually do. The collagen it regulates is the same collagen I am asking to close surgical incisions cleanly. The matrix metalloproteinases it modulates are the same enzymes that determine whether a scar flattens beautifully or raises into a hypertrophic ridge. The skin it remodels is the same skin my patients want restored after significant weight loss, surgery, and the cumulative biology of aging.

This is not an abstract conversation for me. It is a clinical one.

What Is GHK-Cu?

GHK-Cu — formally Glycyl-L-Histidyl-L-Lysine Copper, also called Copper Tripeptide-1 — is a naturally occurring tripeptide-copper complex found in human plasma, saliva, and urine. It is among the smallest and most elegant molecules in the body’s repair toolkit: three amino acids (glycine, histidine, lysine) bound to a single copper (II) ion, working together as a biological signal for tissue regeneration.

Its discovery is one of the better origin stories in peptide science. In 1973, researcher Dr. Loren Pickart at the Albert Einstein College of Medicine noticed something remarkable while studying plasma fractions: when liver cells taken from elderly patients were incubatedin blood from young donors, the old cells began to function like young ones. He isolated the active molecule responsible for that rejuvenation signal. It was GHK — a tiny tripeptide present in young plasma that gradually disappears as we age.

That original observation contained the core insight that has driven decades of GHK-Cu research: this is a molecule that carries a signal of biological youth — one your body naturally produces at high levels when it is young and healing efficiently, and progressively less of as you age.

The Age-Related Decline That Changes Everything

The numbers here are some of the most clinically compelling in anti-aging medicine, and they are rarely cited outside of research circles.

At age 20, plasma GHK levels average approximately 200 ng/mL. By age 60, those levels have declined to approximately 80 ng/mL — a drop of more than 60%.

This decline has been documented in multiple published studies and correlates directly with the age-related decrease in tissue repair capacity, collagen production, wound healing speed, and skin structural integrity that clinicians observe daily. The body does not suddenly forget how to make collagen at 50. It runs out of the signal that tells it to.

GHK-Cu is that signal.

This is not metaphorical. It is the specific molecular compound whose natural decline has been measured in human plasma and correlated with the observable biology of aging skin, impaired wound healing, and reduced regenerative capacity. When patients ask me why their skin doesn’t snap back the way it did at 30, or why surgical wounds take longer to remodel than they used to, the GHK-Cu story is one of the most honest biological answers I can give them.

How Does GHK-Cu Work? Five Mechanisms Worth Understanding

GHK-Cu’s mechanisms of action are broader than any other peptide I have covered in this series. That breadth is both its most remarkable scientific feature and — as I will discuss shortly — something that requires careful interpretation.

1. Collagen Synthesis: The Core Function

GHK-Cu stimulates production of both Type I collagen — the primary structural collagen of skin, bone, and tendon — and Type III collagen, which is essential for tissue flexibility and the early stages of wound repair. Laboratory studies have documented collagen production increases of up to 70% with GHK-Cu exposure in fibroblast cultures. Beyond quantity, GHK- Cu supports collagen cross-linking quality: the copper ion it carries serves as an essential cofactor for lysyl oxidase and lysyl hydroxylase — the enzymes that build the intermolecular bonds that give collagen its tensile strength. Without adequate copper availability, newly synthesized collagen remains structurally weak. GHK-Cu delivers the copper precisely where it is needed to produce collagen that holds.

2. MMP Modulation: The Anti-Scarring Mechanism

This is the mechanism I think about most as a surgeon, and it is one almost never discussed in consumer-facing GHK-Cu content.

Matrix metalloproteinases (MMPs) are the enzymes that break down collagen and extracellular matrix. They are essential to healing — without MMP activity, the body cannot remodel the provisional matrix of a wound into organized, functional tissue. But excessive MMP activity produces fibrosis, hypertrophic scarring, and keloid formation. Too little leads to the accumulation of disorganized collagen that characterizes poor scar architecture.

GHK-Cu modulates MMP activity rather than simply suppressing or amplifying it — driving a balanced remodeling process that promotes normal tissue architecture. In practice, this means GHK-Cu-treated wounds and incisions trend toward flatter, less visible scars with organized collagen structure rather than the dense, elevated, or hyperpigmented scars that plague healing in compromised skin. This is not a cosmetic claim. It is an anti- fibrotic mechanism with direct clinical relevance to surgical outcomes.

3. Angiogenesis: Building Vascular Supply to Healing Tissue

GHK-Cu upregulates VEGF (Vascular Endothelial Growth Factor) expression, promoting new blood vessel formation at sites of injury and tissue remodeling. Adequate vascular supply is the prerequisite for every downstream healing process — nutrient delivery, immune cell recruitment, waste removal, oxygen supply. In post-surgical skin — where incisions, flaps, and undermined tissue may have compromised vascularity — angiogenic support matters directly to healing outcomes.

4. Anti-Inflammatory and Antioxidant Signaling

GHK-Cu modulates NF-κB signaling — one of the primary transcription factor pathways driving systemic and local inflammation — and has been shown to downregulate pro- inflammatory cytokines including TNF-alpha and IL-6 in tissue studies. Simultaneously, it upregulates antioxidant defense genes including superoxide dismutase (SOD), catalase, andelements of the Nrf2 antioxidant response pathway. The result is a healing environment with reduced destructive inflammatory burden and enhanced cellular protection against oxidative damage — both of which are central to quality tissue repair and skin longevity.

5. Gene Expression: The Finding That Sets GHK-Cu Apart

Here is what distinguishes GHK-Cu from every other compound in this series — and, frankly, from nearly every other molecule studied in regenerative medicine.

Using the Broad Institute’s Connectivity Map (CMap) database, researchers Pickart, Vasquez-Soltero, and Margolina analyzed GHK’s effects on gene expression across human cell lines. The finding: GHK-Cu modulates the expression of approximately 4,048 human genes — roughly 31% of the entire human genome — at a threshold of 50% or greater expression change.

No other cosmetic peptide. No other small molecule studied in this context. Nothing else comes close to that breadth of gene expression influence.

The genes affected span an extraordinary range: collagen and elastin synthesis, glycosaminoglycan production, antioxidant defense, DNA repair, inflammatory signaling, cell proliferation and apoptosis, ubiquitin-proteasome function, and mitochondrial metabolism. The pattern of gene modulation — upregulating repair and defense pathways, downregulating inflammatory and pro-fibrotic genes — produces a gene expression profile more characteristic of younger, less-aged cells.

A critical note on what this means and does not mean: The Connectivity Map data is generated from cell lines, not from human in vivo studies. Gene expression changes in PC3 or MCF7 cell lines do not automatically translate to identical changes in human tissue. The breadth of GHK-Cu’s genomic influence is a remarkable scientific signal, but it should be read as a mechanistic map of what is possible, not a confirmed catalog of clinical outcomes. The human evidence for specific GHK-Cu effects — particularly topical skin outcomes — is real and meaningful. The extrapolation of the full 4,048-gene finding to clinical practice requires appropriate epistemic humility.

What Does the Human Evidence Show?

GHK-Cu occupies a unique position in this series: it is the peptide where the strongest human clinical evidence is actually for the topical route — not injectable, not systemic. This changes the patient conversation in important ways.

Topical Human Evidence: Well-Supported

A landmark 2002 clinical trial by Leyden et al. in photoaged skin documented meaningful improvements in skin laxity, fine lines, and structural integrity with topical GHK-Cu application — one of the earliest controlled human studies linking a copper peptide to measurable skin outcomes.

A more recent 2023 IRB-approved trial examining a topical GHK-Cu gel formulation in 21 women documented an average 28% increase in skin collagen density at 3 months of consistent application — a clinically significant structural improvement, not merely a cosmetic one.

Multiple smaller clinical studies have documented improvements in skin thickness, elasticity, and surface roughness with physician-formulated topical GHK-Cu preparations at therapeutic concentrations. The dermatologic evidence base for topical use is more robust and more directly translatable to patient outcomes than the evidence for injectable GHK-Cu.

Injectable Evidence: Preclinical and Mechanistic

The injectable evidence base is primarily preclinical — animal wound models, cell culture studies, and community-derived practitioner observations. The most cited animal study, using an ischemic rat wound model with topical application, documented wound size reduction of 64.5% in the GHK-Cu treated group vs. 28.2% in untreated controls over 13 days — a dramatic healing advantage that has been widely referenced. A separate study documented systemic healing enhancement in rats: GHK-Cu injected in one area of the body improved healing at distant body sites, suggesting systemic signaling beyond local effects.

Injectable GHK-Cu has no published human randomized controlled trials. Clinical use exists — particularly in hair restoration and wound care — but the evidence is practitioner-derived rather than trial-confirmed. This does not invalidate the mechanistic rationale or the clinical observations; it means the injectable evidence base is at an earlier stage of development than the topical literature.

Hair Restoration: Meaningful Clinical Signal

GHK-Cu has been studied for its effects on hair follicle biology, with findings that are directly relevant to my hair restoration practice. Research suggests GHK-Cu can enlarge hair follicle size, extend the anagen (active growth) phase of the hair cycle, stimulate scalp microcirculation through VEGF-mediated angiogenesis, and activate Wnt signaling — a master regulator of follicle morphogenesis in dermal papilla cells.

Clinical practitioners using GHK-Cu in scalp applications — topical and injectable — report reduced shedding at 6–8 weeks and meaningful density improvement at 3–6 months in patients with miniaturized but still viable follicles. An important note: GHK-Cu cannot revivecompletely scarred follicles. It addresses active follicle biology, not structural follicle loss.

The hormetic response is worth noting here: lower concentrations of GHK-Cu stimulate follicle activity; higher concentrations can inhibit it. This is a documented finding in the hair biology literature and has direct implications for dosing — more is not always better, and formulation concentration matters significantly in both topical and injectable applications.

GHK-Cu and the FDA: The Two-Track Regulatory Picture

GHK-Cu has a regulatory profile that is genuinely unique in this peptide series — because it exists simultaneously in two entirely different regulatory categories depending on the delivery route.

Topical GHK-Cu: Fully Legal, No Restrictions

Topical GHK-Cu is classified as a cosmetic ingredient under its INCI name Copper Tripeptide-1. It is fully legal in the United States, available both over the counter and as physician-prescribed compounded topical formulations. There are no compounding restrictions on topical GHK-Cu; licensed pharmacies can formulate it at therapeutic concentrations for physician prescription without regulatory limitation. For the primary indications driving demand — skin rejuvenation, scar remodeling, collagen support, hair restoration — topical delivery reaches the target tissues (dermis, epidermis, hair follicles, scalp) at therapeutic concentrations. This is not a workaround. For skin and hair applications specifically, topical is the evidence-supported and legally clear delivery method.

OTC cosmetic formulations typically contain GHK-Cu at 0.1–2% concentration. Physician- prescribed compounded topicals can be formulated at higher, more therapeutically relevant concentrations with verified purity and pharmaceutical-grade manufacturing. The quality gap between a well-formulated prescription compounded preparation and a mass-market cosmetic serum is significant — this is a conversation worth having with your physician.

Injectable GHK-Cu: The Evolving Regulatory Picture

Injectable GHK-Cu was placed on the FDA’s Section 503A Category 2 restricted list in 2023, citing immunogenicity and manufacturing impurity concerns. On April 15, 2026 — as part of the same wave of regulatory action that affected BPC-157, TB-500, and other compounds — the nominations driving that Category 2 restriction were withdrawn, and injectable GHK-Cu was removed from Category 2, effective April 22, 2026.

However, the path for injectable GHK-Cu diverges from BPC-157 and TB-500: while those compounds are scheduled for PCAC review in July 2026, injectable GHK-Cu is scheduled for separate PCAC review before the end of February 2027. The practical implication is that the formal compounding authorization pathway for injectable GHK-Cu has a longer horizon than the July peptides. Removal from Category 2 means injectable GHK-Cu no longer carries the “significant safety concern” label — but it is not yet on the approved 503A Bulks List. Access through compounding pharmacies for injectable use remains in a transitional status.

The clinical bottom line on route selection: For skin and hair applications — the primary indications in my aesthetic practice — the human evidence base is stronger for topical, the legal pathway is clearer, and well-formulated prescription-compounded topicals deliver therapeutic concentrations to target tissues effectively. Injectable GHK-Cu is a discussion for systemic or deeper tissue applications where topical penetration is insufficient — and those conversations should happen with a physician tracking the regulatory landscape carefully.

GHK-Cu in My Practice: The Plastic Surgery Perspective

I have structured this post around GHK-Cu’s mechanisms because I want patients to understand — viscerally — why this peptide sits differently in my mind than anything else in this series. Let me make that explicit.

Surgical Wound Healing and Scar Architecture

Every incision I make creates a healing opportunity and a scar risk simultaneously. The quality of that scar is determined by the biology of the repair process: the speed of re- epithelialization, the organization of the collagen matrix, the balance between synthesis and remodeling driven by MMP activity, the vascular supply supporting the healing tissue.

GHK-Cu speaks to all of those variables. Its collagen-stimulating effect accelerates structural repair. Its MMP-modulating effect prevents the disorganized fibrosis that becomes a hypertrophic scar. Its VEGF-driven angiogenic effect supports vascular supply to healing tissue. For patients applying physician-formulated topical GHK-Cu to healing incisions under my guidance — beginning at the appropriate post-operative window — this is among the most evidence-supported tools we have for optimizing scar outcomes.

Post-Weight-Loss Skin Quality

Patients who come to me following significant weight loss — whether through GLP-1 medications, bariatric surgery, or lifestyle transformation — frequently present with skin that has lost architectural integrity: thinned dermis, reduced collagen density, impaired elasticity, and compromised wound healing capacity. These patients often face surgery with skin thatheals less predictably than ideal.

GHK-Cu’s ability to stimulate collagen synthesis, restore Type I and III collagen ratios, and improve dermal structural density is directly relevant to this population — both in the pre- surgical optimization window and in the post-operative recovery period. I think about it alongside the hormone optimization and metabolic peptide protocols we have already discussed; skin quality is not separate from systemic biology. It reflects it.

Hair Restoration Integration

Hair restoration is an important part of my practice, and GHK-Cu’s follicle biology — Wnt signaling activation, anagen phase extension, scalp microcirculation enhancement — integrates naturally with platelet-rich plasma (PRP) protocols, minoxidil regimens, and other evidence-based approaches I use. It is not a replacement for any of those tools; it is a biochemically rational addition that addresses the follicle environment through different and complementary mechanisms.

Microneedling Synergy

Microneedling — a procedure I perform regularly — creates controlled micro-channels in the dermis that dramatically enhance penetration of topical actives. GHK-Cu applied to freshly needled skin reaches deeper dermal layers where fibroblasts are actively responding to the micro-injury stimulus. The combination amplifies GHK-Cu’s collagen-signaling effect at precisely the moment the tissue is most receptive to it. This is one of the most evidence- informed topical peptide delivery strategies in aesthetic medicine, and one I use with patients.

Who Is a Good Candidate for GHK-Cu?

Given the split between topical (fully accessible) and injectable (evolving regulatory status), the candidate conversation breaks along those lines:

Topical GHK-Cu — appropriate to discuss for: Any patient focused on skin quality, collagen support, scar remodeling, post-procedure recovery, photoaging, or hair restoration. The legal pathway is clear, the evidence base is meaningful, and the safety profile is excellent. This is a conversation that can happen regardless of the injectable regulatory picture.

Injectable GHK-Cu — appropriate to discuss with greater nuance for: Patients seeking systemic tissue repair support in whom topical application cannot reach the target tissues, or patients building comprehensive peptide protocols where deeper tissue signaling is a goal. The regulatory status is transitional, the evidence base is more practitioner-derived,and the conversation requires a physician who is tracking the PCAC timeline carefully.

Who benefits most overall:

• Post-surgical patients optimizing wound healing and scar outcomes
• Post-weight-loss patients addressing dermal quality pre- or post-body contouring
• Patients over 40 experiencing the measurable consequences of GHK-Cu decline —
• reduced skin density, impaired healing, increased scar tendency
• Hair restoration patients with miniaturized but viable follicles
• Patients already on comprehensive peptide protocols (CJC-1295, BPC-157, TB-500)
• adding the skin and tissue remodeling dimension
• Patients undergoing microneedling, laser resurfacing, or other aesthetic procedures
• where post-procedure topical protocols are part of the treatment plan

What Does a GHK-Cu Protocol Look Like?

Topical (primary evidence-supported route):

• Physician-prescribed compounded formulations: typically 1–3% concentration in an appropriate vehicle; higher concentrations under medical supervision
• Application: once or twice daily to target area (face, neck, décolletage, scalp, post-
• surgical scar)
• Microneedling integration: applied immediately post-treatment for enhanced dermal penetration
• Timeline: measurable skin density improvement typically documented at 8–12 weeks; hair growth changes at 3–6 months; scar remodeling over 3–6 months post-procedure
• Concentration note: The hormetic response documented in hair biology applies to formulation concentration — start at the lower therapeutic range and optimize based on clinical response

Injectable (transitional regulatory status, physician-supervised):

• Community and practitioner-derived protocols: typically 1–2 mg/day subcutaneous
• Cycle: 4–8 weeks on, equivalent period off
• No validated human RCT dosing exists — protocols are drawn from preclinicalevidence and clinical observation
• Confirm current 503A pharmacy availability before initiating

Important: OTC cosmetic GHK-Cu serums are widely available, but concentration accuracy and formulation quality vary significantly across the commercial market. A product listing GHK-Cu as an ingredient may contain concentrations far below therapeutic relevance. For patients seeking clinical outcomes — not just cosmetic marketing — physician-prescribed compounded formulations with verified concentration and pharmaceutical-grade manufacturing are the appropriate standard.

Frequently Asked Questions About GHK-Cu

What does GHK-Cu stand for? Glycyl-L-Histidyl-L-Lysine Copper — three amino acids (glycine, histidine, lysine) bound to a copper ion. Also called Copper Tripeptide-1 in cosmetic ingredient nomenclature.

When was GHK-Cu discovered? First isolated from human plasma by Dr. Loren Pickart at the Albert Einstein College of Medicine in 1973. He observed that older cells incubated with young plasma began functioning like younger cells, and isolated GHK as the active signaling molecule responsible.

Does GHK-Cu actually affect 4,000 genes? The figure — 4,048 human genes, or approximately 31% of the genome — comes from Broad Institute Connectivity Map data analyzed by Pickart, Vasquez-Soltero, and Margolina. This represents the breadth of gene expression changes observed in human cell lines exposed to GHK-Cu at 1 µM concentration. It is a mechanistic finding from cell culture, not a confirmed in vivo clinical outcome map. The gene modulation breadth is scientifically remarkable; translating it directly to human clinical outcomes requires the kind of controlled trials that are still in development.

Is topical GHK-Cu as effective as injectable? For skin and hair applications — where the target tissues are in or near the dermis and scalp — topical delivery at adequate concentration reaches the relevant cell populations directly. The strongest human clinical evidence is for topical use. For systemic tissue repair or deeper anatomical targets, topical penetration is limited and injectable represents a mechanistically different approach. Route selection should be matched to clinical goal.

Is GHK-Cu legal in the US? Topical GHK-Cu is fully legal — available OTC and as physician- prescribed compounded formulations with no restrictions. Injectable GHK-Cu was removed from FDA Category 2 restriction on April 22, 2026, with PCAC review scheduled before February 2027 to determine formal 503A compounding authorization. It is not currently on the approved 503A Bulks List for injectable use.

Can GHK-Cu be used after cosmetic procedures? Yes — and this is one of its most clinically practical applications. Post-microneedling, post-laser, and post-chemical peel protocols incorporating topical GHK-Cu leverage the enhanced dermal penetration of those procedures to deliver collagen-stimulating signals when the tissue is most receptive. Timing and formulation selection should be guided by your treating physician.

How does GHK-Cu affect scarring? Through MMP modulation — GHK-Cu balances collagen synthesis with enzymatic remodeling, producing organized tissue architecture rather than the disorganized dense collagen of hypertrophic scars. Unlike compounds that simply stimulate collagen production, GHK-Cu also drives the degradation of abnormal collagen, making it an anti-fibrotic agent as well as a pro-healing one.

Is GHK-Cu safe? Topical GHK-Cu has an excellent safety profile confirmed across decades of cosmetic and clinical use — mild skin irritation is the most commonly reported adverse effect. Injectable GHK-Cu has no severe adverse events documented in available literature. The compound is not on WADA’s Prohibited List, making it one of the few peptides in this series with no athletic restriction.

Closing the Series: What Six Peptides Together Look Like

This post completes the first volume of the DiFrancesco Plastic Surgery Peptide Series. Let me close with the frame I use when I am thinking about all of these compounds together for a patient pursuing comprehensive integrated care:

The growth hormone tier (CJC-1295 + Ipamorelin): Restoring the pulsatile GH rhythm that drives body composition, sleep quality, metabolic efficiency, and cellular repair capacity.

The metabolic and fat loss tier (AOD-9604): Targeted lipolysis and body recomposition without interfering with insulin or IGF-1.

The tissue repair tier (BPC-157 + TB-500): Local and systemic healing support — BPC- 157’s precise repair signaling, TB-500’s systemic cell mobilization and angiogenesis.

The immune tier (Thymosin Alpha-1): Restoring the T-cell function that age and thymic involution have eroded, supporting immune surveillance, vaccine response, and recovery resilience.

The skin and tissue remodeling tier (GHK-Cu): Collagen architecture, scar quality, wound healing optimization, hair follicle biology, and the gene-level reset that characterizes youthful tissue repair.

These mechanisms do not compete. They operate on different biological axes and compound one another’s effects when the clinical picture supports the full protocol. Not every patient needs every tier. The art — and the medicine — is in matching the biology to the person in front of you.

That is what I do here. That is what this series is for.

This is the sixth and final post in Volume One of the DiFrancesco Plastic Surgery Peptide Series. Volume Two will cover Ipamorelin, Epitalon, Semax, KPV, and MOTS-C. Subscribe to receive future installments.

Lisa DiFrancesco, MD is a board-certified plastic surgeon and founder of DiFrancesco Plastic Surgery in Atlanta, Georgia. Her practice specializes in post-weight-loss aesthetics, hormone optimization, hair restoration, and physician-led integrated aesthetic medicine.

This content is for educational purposes only and does not constitute medical advice. Consult a licensed physician before initiating any peptide protocol. Individual results vary. Regulatory status of compounded peptides is subject to change pending FDA PCAC review; confirm current pharmacy availability before initiating injectable therapy.

© 2026 DiFrancesco Plastic Surgery | Atlanta, GA

Schedule A Consultation

Subscribe now

Share

spent the last few months digging into the glp1 api supply chain from china. the demand is insane — semaglutide, tirzepatide, retatrutide — and china supplies over half the global api for this stuff. but the gap between the legit factories and the scammers is massive

here's what i learned. sharing because i keep seeing people get burned in other subs

the short version — there's about 5 companies that actually make this stuff at scale. hanyu pharma and sinopep (nuotai) alone do like 70% of the global supply. these are publicly traded companies with real gmp facilities. theyre not sending you "samples" in plastic bottles from some warehouse in shenzhen

how the scam works — someone claims to be a factory rep, sends you a coa that looks professional, asks for 50% upfront, then disappears or sends you underdosed powder. ive seen coas that were literally photoshopped. the original was from a completely different company

how to actually verify a supplier:

ask for their dmf number. drug master file. if theyre exporting to the us through compounding pharmacies they need one. you can cross check it. no dmf = either theyre not a real exporter or theyre just flipping someone elses product

gmp certificate. not "gmp compliant" — an actual certificate with a number you can verify. huge difference

hplc report from a third party lab, not their own. if they only show you their own testing, ask why. legit factories use third party testing all the time

minimum order is a tell. real api factories deal in grams and kilograms, not "10 vials for $200." if someone is selling you tiny amounts in pre packaged vials you're talking to a reseller at best

also worth knowing — china's nmpa still hasnt approved generic semaglutide injections, but api export is completely legal and happening at massive scale. the patent expired here in march. so the supply side is getting more competitive which is good for buyers

anyway not selling anything. ive been in the china medical supply chain space for a while (mostly devices) and figured id share what ive found on the pharma side too. if you're thinking about sourcing and want to know what questions to ask, dm is open

Reta + Tesa has been treating me well. Anyone else researching this combo? What are you stacking?

I used the same 1ml syringe to transfer 3.5 ml of bac to ghk cu. wiped down both with prep pad used it on the vial stopper once each before but used same syringe will my ghk still be good?

I keep seeing this one in comments and DMs: "reta killed my sex drive," or "I got on a triple agonist and stopped caring about my partner." Here is where the idea comes from and what the evidence actually says, because it is more split than either the alarmist or the dismissive takes suggest.

First, the caveat that shapes everything: there is no retatrutide-specific data on libido or attachment. The TRIUMPH trials reported weight, glycemia, knee OA, and sleep apnea, not sexual function. Every claim pinned to reta is extrapolated from the GLP-1 class, mostly semaglutide.

Where it comes from. The starting point is "food noise" going quiet. By 2025, reports broadened past food: less alcohol craving, less impulse shopping, less social interest, and in some cases lower libido and a general flattening of emotional range. That cluster is what gets called "falling out of love."

https://peptidenewsdigest.org/insights/glp1-emotional-flattening/

The mechanism that makes it plausible. GLP-1 agonism modulates dopamine in the reward circuits that drive "wanting," the same system behind sexual motivation, which is why the addiction researchers keep showing up in these threads. A 2025 narrative review argues GLP-1s reduce sexual desire through reward-pathway and serotonergic (5-HT2C) effects, but that it is usually camouflaged by other changes. Note this is a theoretical review, not a trial.

https://www.sciencedirect.com/science/article/pii/S2667368125000774

Two claims get blended. "Falling out of love" is really two things. One is neurochemical: the drug blunts reward circuitry that desire runs on. That rests on mechanism plus anecdote, not trial data. The other is psychosocial: big fast weight loss shifts relationships. A Swedish researcher's "divorce boom" hypothesis attributes it to confidence, autonomy, and social attention after weight loss, plus a partner who did not change, drawing on bariatric data. That is real, but it is not the drug switching off love. These point to very different conclusions.

https://www.foxnews.com/health/divorce-boom-may-follow-use-ozempic-glp-1-drugs-experts-warn

The data pointing the other way. A lot of the hard data runs opposite. Weight loss tends to improve sexual function through mood, self-image, and hormones, and clinicians report most patients see better desire after weight loss, not worse. On hormones, the male data leans positive: Endocrine Society reviews found GLP-1s increase or stabilize testosterone in men with obesity or T2D, with no negative impact on sexual function or sperm quality. The rise is modest, roughly 320 to 368 ng/dL in one analysis.

https://www.medscape.com/viewarticle/when-glp-1s-change-patients-libido-what-know-2025a1000pa

https://www.nature.com/articles/d41586-026-01867-0

The complication. Not clean the other way either. A TriNetX cohort of non-diabetic obese men aged 18 to 50 found semaglutide associated with more new ED or PDE5 inhibitor starts, 1.47 percent versus 0.32 percent. The relative risk sounds big, but the absolute numbers are small. The review reporting it is titled "Friend or Foe" for a reason. And the depression and emotional-blunting claims sit mostly in anecdote and FAERS reports; controlled semaglutide analyses have not found increased depression versus placebo.

https://pmc.ncbi.nlm.nih.gov/articles/PMC12467596/

How I read it. Bidirectional and individual, not a uniform "reta kills desire." There is a plausible mechanism for reduced desire in a subset, backed by mechanism and anecdote but no controlled libido trials and nothing reta-specific. There is a better documented path toward improved desire for many, through weight, mood, and testosterone. And "falling out of love" blends a thin neurochemical claim with a better documented psychosocial one that deserves to be kept separate. If you notice a real change on cycle, track it and raise it with a clinician rather than dismissing or catastrophizing, but the current evidence does not establish that the drug makes you fall out of love.

I've been on GHK CU for about 4 weeks. I just ordered KLOW as it has other peps I think I'll benefit from. Do I need to do an off cycle before I start KLOW since they both have GHK CU? TIA

To get verified in their Discord, you have to authorize a bot called “JKL Robot” that requests permission to join servers on your behalf, not just view your profile. That’s a risk because normal verification bots don’t need that access, it’s the same permission used in “token grabber” scams to hijack accounts and spam or scam other people without the owner knowing.

When I brought this up, their team said it’s to auto re-add members if the server gets raided. Maybe true, but it still means handing an unverified bot ongoing access to your account.

Given that, I’d think twice about doing business with them at all, not just avoiding the Discord link. It says a lot about how loosely they handle security overall.

Looking for anyone who is an advanced expert to share their knowledge on a podcast to help educate people the right way- with the truth!

Background in peptide pharmacology, COA analysis and testing, endocrinologist/internal medicine specialists, researcher or similiar.

Basically you have to be an authoritative figure!

Not here to sell or promote anyone or anything- Just education that is 100% researched based.

YT Channel is in the social links

Please reach out if interested

Some of you may know I've been working on Peptide IQ, a free peptide tracking app I originally built because I was tired of tracking everything in messy spreadsheets.

The web app already has PK style graphs, half-life decay curves, dose stacking, shot scheduling, stack builder, weight tracking, and a free public dosing calculator with no sign up.

Now I'm launching the mobile app next week!

The goal is simple, make logging fast and easy in the moment, instead of remembering everything later.

Here is a preview collage with shots of the mobile app and the web app so people can see the full picture.

I'd love feedback from peptide and health-tracking folks. What would make the mobile app actually useful for you? And if you use spreadsheets, what's the most annoying part?

You can also request peptides to be added to the list of 50+, build your own stack, and reconstitute your settings every time you start a new vial if its a diff mg.

This is not medical advice and I am not a medical professional please reach out to your local professionals for any advice.